Results 61 to 70 of about 146,093 (222)

Differences Among Angiotensin II Type 1 Receptor Blockers: Characteristics of Candesartan Cilexetil

Blood Pressure, 2000
Several angiotensin II type 1 (AT 1 ) receptor blockers are now available for the treatment of hypertension. Although the agents in this class all act by blocking the AT 1 -receptor, they differ in their pharmacokinetics and binding characteristics. One of the newest AT 1 -receptor blockers, candesartan cilexetil, is administered in an inactive form ...
openaire   +3 more sources

Suppression of Experimental Autoimmune Uveitis by Angiotensin II Type 1 Receptor Blocker Telmisartan

Investigative Opthalmology & Visual Science, 2009
Angiotensin II type 1 receptor (AT1-R) blockers are used widely for the treatment of patients with hypertension. Recent reports have suggested that AT1-R also plays a key role in various inflammatory conditions. The aim of this study was to examine whether blockade of AT1-R is effective in the suppression of murine experimental autoimmune uveoretinitis
Yoko, Okunuki, Yoshihiko, Usui, Norihiro, Nagai, Takeshi, Kezuka, Susumu, Ishida, Masaru, Takeuchi, Hiroshi, Goto   +6 more
openaire   +2 more sources

Angiotensin II receptor blocker attenuates intrarenal renin-angiotensin-system and podocyte injury in rats with myocardial infarction. [PDF]

PLoS ONE, 2013
The mechanisms and mediators underlying common renal impairment after myocardial infarction (MI) are still poorly understood. The present study aimed to test the hypothesis that angiotensin II type 1 receptor blockers (ARBs) provides renoprotective ...
Zhu-zhi Wen, Mu-yan Cai, Zun Mai, Dong-mei Jin, Yang-xin Chen, Hui Huang, Deng-feng Geng, Jing-feng Wang   +7 more
doaj   +1 more source

The effect of angiotensin receptor blockers on C-reactive protein and other circulating inflammatory indices in man

Vascular Health and Risk Management, 2009
Alessandra Del Fiorentino, Silvana Cianchetti, Alessandro Celi, Giulia Dell’Omo, Roberto PedrinelliDipartimento Cardio Toracico e Vascolare, Università di Pisa, ItalyAbstract: Anti-inflammatory properties may contribute to the ...
Alessandra Del Fiorentino, Silvana Cianchetti, Alessandro Celi, Giulia Dell’Omo, Roberto Pedrinelli   +4 more
doaj  

The angiotensin II Type 1 receptor blocker losartan in clinical practice: a review

Clinical Therapeutics, 1996
Blockade of angiotensin II receptors was first achieved in the 1970s using a peptide, saralasin acetate. Although it was effective in lowering blood pressure, it required parenteral administration and had a short duration of action and partial agonist activity.
H P, Gavras, C M, Salerno
openaire   +2 more sources

Candesartan inhibits inflammation through an angiotensin II type 1 receptor independent way in human embryonic kidney epithelial cells

Anais da Academia Brasileira de Ciências, 2019
: Besides stimulating vasoconstriction, Angiotensin II is also well known in inducing reactive oxygen species and promoting inflammatory phenotype switch via its type 1 receptor.
YING YU, HAIFENG JIANG, YANGYANG NIU, XIAOQIN ZHANG, YINGYING ZHANG, XI LIU, TAO QI, CHEN YU   +7 more
doaj   +1 more source

AT1-receptor response to non-saturating Ang-II concentrations is amplified by calcium channel blockers

BMC Cardiovascular Disorders, 2017
Background Blockers of angiotensin II type 1 receptor (AT1R) and the voltage gated calcium channel 1.2 (CaV1.2) are commonly used for treatment of hypertension.
Kristoffer Bernhem, Kalaiselvan Krishnan, Alexander Bondar, Hjalmar Brismar, Anita Aperia, Lena Scott   +5 more
doaj   +1 more source

The plague of unexpected drug recalls and the pandemic of falsified medications in cardiovascular medicine as a threat to patient safety and global public health: A brief review

Cardiology Journal, 2022
Valsartan, losartan, and irbesartan, are widely used in the treatment strategies of cardiovascular medicine diseases, including hypertension and heart failure.
Damian Świeczkowski, Szymon Zdanowski, Piotr Merks, Łukasz Szarpak, Régis Vaillancourt, Milosz J. Jaguszewski   +5 more
doaj   +1 more source

Urinary angiotensin-converting enzyme 2 increases in diabetic nephropathy by angiotensin II type 1 receptor blocker olmesartan [PDF]

Journal of the Renin-Angiotensin-Aldosterone System, 2014
Introduction: Angiotensin-converting enzyme 2 (ACE2) is a member of the renin–angiotensin system that degrades angiotensin (Ang) II to the seven-amino acid peptide fragment Ang-(1-7). We evaluated the changes in urinary ACE2 levels in response to treatment with the angiotensin II type 1 receptor blocker olmesartan in diabetes patients with nephropathy.
Masanori, Abe, Osamu, Oikawa, Kazuyoshi, Okada, Masayoshi, Soma   +3 more
openaire   +2 more sources

Telmisartan reduces systemic inflammation and alters the renin-angiotensin system in mild COVID-19

Scientific Reports
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes COVID-19, a respiratory viral infection that disrupts renin angiotensin system (RAS) peptide metabolism by downregulating angiotensin converting enzyme-II (ACE2), leading to accumulation
Angela Lu, Melissa Agsalda-Garcia, Weiyuan Hu, Catherine Chester, Aditya Anil Naik, Brooks I. Mitchell, Isaac Asante, Scott A. Souza, Kuo-Chiang Lian, Zao Zhang, Hannah V. Schmitz, Malia L. Ramirez, Richa Varshney, Serena DelMundo, Dominic C. Chow, Cecilia M. Shikuma, Stan G. Louie   +16 more
doaj   +1 more source